GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. ...
GT Biopharma, Inc. (NASDAQ: GTBP) is a biotechnology company focused on discovering and developing immuno-oncology treatments for cancer. The company operates in the clinical development phase, emphasizing therapeutic approaches that harness the patient’s immune system to recognize and attack tumor cells. Its core differentiation is a proprietary TriKE (Tri-specific Killer ...GT Biopharma, Inc. (NASDAQ: GTBP) is a biotechnology company focused on discovering and developing immuno-oncology treatments for cancer. The company operates in the clinical development phase, emphasizing therapeutic approaches that harness the patient’s immune system to recognize and attack tumor cells. Its core differentiation is a proprietary TriKE (Tri-specific Killer Engager) fusion-protein technology platform. TriKE molecules are engineered to bind tumor-associated targets and engage immune effector cells, aiming to promote targeted cytotoxic activity while improving specificity relative to less targeted immunotherapies.
At the center of the company’s pipeline is GTB-3550, a single-chain, tri-specific recombinant fusion protein conjugate currently in Phase I/II clinical trials. Based on the company’s description, GTB-3550 is being evaluated in myeloid and other CD33-expressing malignancies, including myelodysplastic syndromes and acute myeloid leukemia that is relapsed or refractory to prior treatments, as well as advanced systemic mastocytosis and other CD33-expressing cancers. The clinical-stage nature of the program indicates that the company’s near-term execution focuses on safety, dose finding, and early efficacy signals to support further development.
GT Biopharma also advances additional platform-derived assets. For example, GTB-3650 is described as a preclinical candidate targeting CD33 on myeloid leukemias, reflecting the company’s strategy to expand within its key target biology. In parallel, the company has disclosed a preclinical asset, GTB-5550, aimed at solid tumors that are positive for B7-H3. This highlights a broader intention to apply TriKE engineering across multiple tumor antigen classes.
From a business and cost perspective, GT Biopharma fits the typical profile of an R&D-intensive, early-stage biopharmaceutical company. Revenue generation is generally limited prior to commercialization, while expenses are driven by discovery work, preclinical studies, clinical trial operations, manufacturing development, regulatory activities (e.g., IND-related work), and supporting functions. Public market metrics for the company show negative profitability and negative free cash flow trends consistent with ongoing investment in clinical and preclinical activities.
Strategically, the company has cited collaborations and licensing arrangements that can support development timelines and broaden indications. These include a co-development agreement with Altor BioScience Corporation for clinical advancement of a TriKE fusion protein and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology.
Historically, GT Biopharma was founded in 1965 and previously operated under the name OXIS International, Inc. before rebranding to GT Biopharma, Inc. in July 2017. Leadership includes Michael Martin Breen as CEO (Executive Chairman/CEO role noted in management references), reflecting ongoing efforts to steer the organization through pipeline maturation, clinical milestones, and platform development. With a very small employee base reported publicly (within 0–100, and possibly around 1 in the provided snapshot), the company likely relies on lean internal operations and external partners to advance its programs.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
—
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-28.4M
-115.4%
-59.5%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-12.9M
-0.1%
-72.6%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
0.0%
—
—
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
3.50x
+387.5%
-29.4%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
